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Incubation of plasma from the steelhead trout, Oneorhynehus mykiss with porcine pancreatic glandular kallikrein generated bradykinin-like 
immunoreactivity. The primary structure of the immunoreactive p ptide was established as: Lys-Arg-Pro-Pro-Gly-Trp-Ser-Pro-Leu-Arg. This 
sequence shows two amino acid substitutions (Phe6--~Trp and Phe9--*Leu) compared with mammalian lysyl-bradykinin (kallidin). Bolus intra- 
arterial injection of the purified peptide produced a strong and sustained vasopressor response in the unanaesthetized trout. The data demonstrate 
that the kallikrein-kinin system predates the appearance of tetrapods and suggest a role for this system in cardiovascular regulation in fish. 
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1. INTRODUCTION 
The existence of a kallikrein-kinin system in birds 
and reptiles has been established unequivocally. In the 
chicken, treatment of plasma kininogen with bovine 
plasma kallikrein generates [Thr6,Leu8]bradykinin (or- 
nitho-kinin) [1]. Activation of endogenous kallikrein by 
incubation of plasma from the turtle [2] and alligator [3] 
with glass beads generates [Thr6]bradykinin. Synthetic 
replicates of the avian and reptilian kinins show potent 
vasodilator activity in their species of origin. The exis- 
tence of a kallikreimkinin system in other classes of 
lower vertebrates is less clear. Attempts to generate ki- 
nins in frog and fish plasma that were active on the 
isolated rat uterus have produced conflicting results 
[4,5]. More recently, however, it has been shown that 
trout tissues contain kallikrein-like sterolytic activity, 
determined with a range of synthetic substrates and 
specific kallikrein inhibitors, and kininogen, demon- 
strated by generation of bradykinin-like immunoreac- 
tivity after incubation with trypsin or porcine glandular 
kallikrein [6,7]. The substance(s) generated in trout 
plasma by kallikrein treatment, termed T60K, produced 
a dose-dependent pressor esponse in both trout and 
rats and T60K-contracted isolated trout and rabbit ar- 
teries [8]. In this study, we have used an antisera raised 
against mammalian bradykinin to facilitate the purifica- 
tion of a bradykinin-related vasoactive peptide from 
kallikrein-treated trout plasma that is probably identi- 
cal to T60K. 
*Corresponding author. Fax: (1) (402) 280-2690. 
2. MATERIALS AND METHODS 
2.1. Generation fthe kinin 
Plasma (60 ml) from 5 adult steelhead trout (Oncorhynchus mykiss, 
skamania strain) was incubated with porcine pancreatic glandular 
kallikrein (5 U/ml plasma) for 1 h at 37°C as previously described [8]. 
The reaction mixture was diluted with an equal volume of 1% (v/v) 
trifluoroacetic a id/water and peptide material was isolated using Sep- 
Pak C 18 cartridges as described [2]. 
2.2. Radioimmunoassay 
Bradykinin-like immunoreactivity was determined by radioimmu° 
noassay using antiserum BT4, raised against mammalian bradykinin, 
using a procedure previously described [9]. 
2.3. Purification of the peptide 
The plasma extract was redissolved in 1% (v/v) trifluoroacetic a id/ 
water (4 ml) and chromatographed on a (90 x 1.6 cm) column of 
Sephadex G25 (Pharmacia-LKB) equilibrated with 1 M acetic acid at 
a flow rate of 24 ml/h. Fractions (2 ml), were collected and the presence 
of bradykinin-like immunoreactivity was determined by radioimmu- 
noassay at appropriate dilutions. Immunoreactive fractions were 
pooled (total volume = 14 ml) and pumped at a flow rate of 2 ml/min 
onto a (250 x 10 mm) Vydac 218TP510 C18 column (Separations 
Group) equilibrated with 0.1% (v/v) trifluoroacetic acid/water. The 
concentration f acetonitrile in the eluting solvent was raised to 14% 
(v/v) over I0 min and to 35% (v/v) over 50 rain using linear gradients. 
Absorbance was measured at 214 and 280 nm and 2 ml fractions were 
collected. The fraction denoted by the bar (Fig. IA) was re-chromato- 
graphed on a (250 × 4.6 mm) Vydac 214TP54 C4 column equilibrated 
with 0.1% (v/v) trifluoroacetic a id/water at a flow rate of 1.5 ml/min. 
The concentration f acetonitrile in the eluting solvent was raised to 
28% (v/v) over 40 min using a linear gradient. Trout lysyl-bradykinin 
was purified to apparent homogeneity by successive chromatogra- 
phies on a (250 x 4.6 mm) Vydac 218TP54 C18 column and then on 
a (250 x 4.6 mm) Supelcosil LC-18-DB C18 column (Supelco Inc.) 
under the same conditions used with the C4 column. 
2.4. Structural characterization 
The primary structure of the peptide was determined by automated 
Edman degradation. Its amino acid composition was determined in
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duplicate by pre-column derivatization with phenylisothiocyanate. 
Tryptophan and cysteine residues were not determined. The methods 
and instrumentation used have been described previously [2,3]. 
2.5. Effects on arterial blood pressure 
The dorsal aorta of 300 g male rainbow trout (O. mykiss, unknown 
strain) was cannulated percutaneously as described [6] and the fish 
allowed to recover for 48 h. Approximately 500 pmol of purified trout 
lysyl-bradykinin in 0.25 ml 0.9% (w/v) NaC1 was injected in a single 
bolus. Arterial blood pressure was measured as described [6]. A second 
injection of 250 pmol of peptide was made after an interval of 6 h. 
Vehicle controls were injected 2 h after each lysyl-bradykinin treat- 
ment. 
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3. RESULTS 
3.1. Generation of the kinin 
Incubation of  trout plasma, in which proteolytic en- 
zymes had been inactivated by heat treatment, with por- 
cine glandular kallikrein generated bradykinin-like im- 
munoreactivity equivalent to approximately 5 ng of  
bradykinin/ml of  plasma. However, serial dilutions of  
the immunoreactivity did not diminish in parallel with 
the synthetic bradykinin standard in radioimmunoas- 
say. Bradykinin-like immunoreactivity was not detected 
in trout plasma that had not been incubated with kal- 
likrein. 
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3.2. Purification of trout bradykinin 
Bradykinin-like immunoreactivity in the plasma ex- 
tract was eluted from a Sephadex G-25 gel permeation 
column as a single major peak with K~v between 0.80 
and 0,95. The fractions containing maximum im- 
munoreactivity were pooled and chromatographed on 
a semi-preparative C18 column (Fig. 1A). Bradykinin- 
like immunoreactivity was associated with the promi- 
nent peak denoted by the bar and with a minor peak 
that eluted later. Chromatography of  the more abun- 
dant component on an analytical C4 column (Fig, 1B) 
showed that bradykinin-like immunoreactivity was as- 
sociated with the well-resolved peak delineated by the 
arrows. Successive chromatographies of  the fraction on 
an analytical Vydac C18 column (Fig. 1C) and on an 
analytical Supelcosil C18 column (Fig. 1D) led to the 
purification to apparent homogeneity of  the trout 
bradykinin-related peptide. The final yield of  pure ma- 
terial was approximately 2 nmol. Attempts to purify the 
minor peak with bradykinin-like immunoreactivity 
(Fig. I A) were not successful. 
Fig. 1. Purification by reverse-phase HPLC of trout bradykinin on (A) 
semipreparative Vydac C18, (B) analytical Vydac C4, (C) analytical 
Vydac C18, and (D) analytical Supelcosil C18 columns. BK-LI de- 
notes the peaks containing bradykinin-like immunoreactivity. The 
arrows show where peak collection began and ended, and the dashed 
line indicates the concentration of acetonitrile in the eluting solvent. 
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Fig. 2. Effect of an intra-arterial injection (arrow) of purified trout lysyl-bradykinin (approx. 500 pmol) on arterial blood pressure (mmHg) in an 
unanesthetized trout. The response in a single experiment is shown. 
3.3. Peptide characterization 
The primary structure of trout lysyl-bradykinin was 
determined by automated Edman degradation. The 
amino acid sequence of the peptide was established as: 
Lys (146)-Arg (240)-Pro (307)-Pro (319)-Gly (327)-Yrp 
(90)-Ser (36)-Pro (169)-Leu (101)-Arg (78). The values 
in parentheses show the yields of phenylthiohydantoin 
amino acids in pmol. The amino acid composition of the 
peptide was determined as: Ser 1.2 (1), Gly 1.4 (1), Arg 
2.5 (2), Pro 3.1 (3), Leu 1.0 (1), Lys 0.7 (1) residues/mol 
peptide. The values in parentheses show the values pre- 
dicted from the proposed structure. The strong absorb- 
ance at 280 nm of the purified peptide was consistent 
with the presence of a tryptophan residue. 
3.4. Biological activity 
Intra-arterial injection of trout lysyl-bradykinin pro- 
duced a bi-phasic pressor esponse (Fig. 2). An initial 
rapid but transient increase in arterial blood pressure 
was followed by a sustained hypertensive p riod exceed- 
ing 30 min. The response to both injections of the pep- 
tide was the same. Injection of vehicle alone had no 
effect on blood pressure. 
4. DISCUSSION 
This study has described the first isolation and struc- 
tural characterization of a bradykinin-related peptide 
from a fish, and demonstrates that the appearance of 
the kallikrein-kinin system predates the appearance of 
tetrapods. As shown in Table I, trout lysyl-bradykinin 
shows two substitutions compared with human kallidin 
(Phe6--->Trp and Phe9-->Leu). The peptide shares with 
chicken bradykinin (ornitho-kinin) [1] the presence of 
a penultimate l ucine residue but, unlike chicken and 
reptilian [2,3] bradykinins, contains a serine rather than 
a threonine residue. Although a peptide related to mam- 
Table I 
A comparison of the amino acid sequences ofpeptides related to trout 
lysyl-bradykinin 
Trout  l ysy l -b radyk in in  
Human Lysy l -b radyk in in  
ch icken  orn i tho -k in in  
A l l iga tor / tu r t le  b radyk in in  
Lys -Arg -Pro -Pro -G ly -T rp -ser -P ro -Leu-Arg  
. . . . .  Phe  - - Phe  - 
. . . .  Phe  Thr  - 
. . . .  Phe  Thr  - Phe  - 
(-) denotes residue identity. 
malian lysyl-bradykinin rather than to bradykinin was 
isolated in the present study, the peptide was generated 
under non-physiological conditions i.e. incubation with 
pig glandular kallikrein. Further studies are required to 
determine whether lysyl-[TrpS,LeuS]bradykinin or [Trp s, 
LeuS]bradykinin are generated in trout plasma when the 
animal's own kallikrein-kinin system is activated under 
physiological conditions. It may be significant, how- 
ever, that the eel intestine contracts in response to kal- 
lidin whereas ynthetic bradykinin is without effect [10]. 
The vasopressor response of trout lysyl-[Trp6,Leu9] - 
bradykinin in the trout contrasts with hypotensive ac- 
tion of lysyl-bradykinin in mammalian species (re- 
viewed in [11]) but is consistent with the known pressor 
effect of mammalian kinins in trout [12]. The vaso- 
dilator action of bradykinin (and kallidin) in mammals 
is mediated primarily through interaction with both B,- 
and Bz-subtype receptors, and involves endothelial pro- 
duction of the potent vasodilators, prostacyclin [13] and 
nitric oxide [14]. Although prostanoid vasodilators can 
be released from trout endothelium by the calcium iono- 
phore, A23187, this release is not stimulated by mam- 
malian bradykinin, nor is nitric oxide released by trout 
endothelium [15]. Thus it appears that bradykinin orig- 
inally evolved as a vasoconstrictor hormone and was 
more recently adapted to a vasodilator role by terres- 
trial vertebrates. 
Acknowledgements: Thiswork was supported by a National Science 
Foundation Grants IBN 9105247 and IBN 9117387. 
REFERENCES 
[1] Kimura, M., Sueyoshi, T., Takada, Tanaka, K., Morita, T. and 
Iwanaga, S. (1987) Eur. J. Biochem. 168, 493-501. 
[2] Conlon, J.M., Smith, D.D. and Hicks, J.W. (1990) Endocrinol- 
ogy 126, 985-991. 
[3] Comeau, S., Lance, V.A., Hicks, J.W. and Conlon, J.M. (1992) 
Am. J. Physiol. 263, R400-R404. 
[4] Seki, T., Miwa, I., Nakajima, T. and Erdos, E.G. (1973) Am. J. 
Physiol. 224, 1425-1430. 
[5] Dunn, R.S. and Perks, A.M. (1975) Gen. Comp. Endocrinol. 26, 
165 178. 
[6] Lipke, D.W. and Olson, K.R. (1990) Am. J. Physiol. 258, R501 
R506. 
[7] Lipke, D.W. and Olson, K.R. (1992) Fish Physiol. Biochem. 10, 
339 346. 
[8] Lipke, D.W., Meisheri, K.D. and Olson, K.R. (1990) Am. J. 
Physiol. 258, R507-R514. 
[9] Balks, H.J., Conlon, J.M., Creutzfeldt, W. and Stockmann, F. 
(1988) Clin. Endocrinol. 28, 141 151. 
77 
Volume 334, number 1 FEBS LETTERS November 1993 
[10] Cougnon, N., Deacon, C.F. and Henderson, I.W. (1990) J. Endo- 
crinol. 127, 74. 
[11] Regoli, D. and Barabe, J. (1980) Pharmacol. Rev. 32, 146. 
[12] Lipke, D.W., Oparil, S. and Olson, K.R. (1990) Am. J. Physiol. 
258, R515-R522. 
[13] Bartha, K., Muller-Peddinghaus, R. and Van Rooijen, A. (1989) 
Biochem. J. 263, 149-155. 
[14] D'Orleans-Juste, P., de Nucci, G. and Vane, J.R. (1989) Br. J. 
Pharmacol. 96, 92~926. 
[15] Olson, K.R. and Villa, J. (1991) Am. J. Physiol. 260, R925 R933. 
78 
